# ATX-295

Source: https://onco.cc/drugs/atx-295/  
OnCo record `atx-295` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ATX-295 is an experimental oral small molecule from Accent Therapeutics, in phase 1 trials for high-grade serous ovarian cancer, squamous non-small cell lung cancer and advanced or metastatic solid tumours.

## Summary

ATX-295 is an oral small molecule from Accent Therapeutics. An inhibitor of KIF18A, a motor protein needed for cell division in tumours with chromosomal instability; the company says aneuploid cancer cells die quickly while cells with normal chromosome numbers are spared. Its furthest stage is phase 1, for high-grade serous ovarian cancer (including platinum-resistant), squamous non-small cell lung cancer and advanced or metastatic solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT06799065 recruiting; Accent retains full worldwide rights. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: ATX-295
- Modality: Oral small molecule
- Mechanism: An inhibitor of KIF18A, a motor protein needed for cell division in tumours with chromosomal instability; the company says aneuploid cancer cells die quickly while cells with normal chromosome numbers are spared.

## Sources

- Accent Therapeutics: accenttx.com: https://accenttx.com/approach-pipeline/
- Accent Therapeutics: accenttx.com: https://accenttx.com/approach-pipeline/
- Accent Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06799065
- ClinicalTrials.gov: trials of ATX-295: https://clinicaltrials.gov/search?intr=ATX-295

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [KIF18A](https://onco.cc/targets/kif18a/)
- companies: [Accent Therapeutics](https://onco.cc/companies/accent-therapeutics/)
- trials: [First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer](https://onco.cc/trials/nct06799065/)

---
JSON: https://onco.cc/api/v1/entities/atx-295.json